Based on these results, we hypothesized that injecting a high concentration of FH could decrease complement activation at an early stage (early: 6 months) or later stage (late: 9 months) and thus could protect the hippocampus from irreversible complement overactivation damage leading to AD cognitive impairments. The gene discussed is FH; the disease is Alzheimer disease.